On Friday, Pacific Biosciences of California Inc (NASDAQ: PACB) opened lower -6.21% from the last session, before settling in for the closing price of $3.38. Price fluctuations for PACB have ranged from $3.21 to $14.55 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 24.48%. Company’s average yearly earnings per share was noted 14.60% at the time writing. With a float of $251.67 million, this company’s outstanding shares have now reached $267.74 million.
Considering the fact that the conglomerate employs 796 people, you should pay attention to its efficiency factor.
Pacific Biosciences of California Inc (PACB) Insider Activity
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Pacific Biosciences of California Inc is 6.08%, while institutional ownership is 98.34%. The most recent insider transaction that took place on Mar 06 ’24, was worth 176,160. In this transaction Director of this company bought 40,000 shares at a rate of $4.40, taking the stock ownership to the 40,000 shares. Before that another transaction happened on Mar 04 ’24, when Company’s insider sold 14,177 for $4.87, making the entire transaction worth $69,056. This insider now owns 2,596,670 shares in total.
Pacific Biosciences of California Inc (PACB) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.00% during the next five years compared to -9.76% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
Check out the current performance indicators for Pacific Biosciences of California Inc (PACB). In the past quarter, the stock posted a quick ratio of 7.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
Compared to the last year’s volume of 8.49 million, its volume of 6.54 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 17.15%. Additionally, its Average True Range was 0.31.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 0.53%, which indicates a significant decrease from 5.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.57% in the past 14 days, which was lower than the 83.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.71, while its 200-day Moving Average is $8.33. Nevertheless, the first resistance level for the watch stands at $3.30 in the near term. At $3.44, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.52. If the price goes on to break the first support level at $3.08, it is likely to go to the next support level at $3.00. Should the price break the second support level, the third support level stands at $2.86.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
There are currently 267,952K shares outstanding in the company with a market cap of 849.40 million. Presently, the company’s annual sales total 200,520 K according to its annual income of -306,740 K. Last quarter, the company’s sales amounted to 58,360 K and its income totaled -82,020 K.
